Zhou P, Yu J, Yan B
Open Med (Wars). 2025; 20(1):20241135.
PMID: 40061828
PMC: 11889506.
DOI: 10.1515/med-2024-1135.
Ghoreishi Amin N, Khosravi S, Atefi N, Seirafianpour F, Farhoodi S, Goodarzi A
Immun Inflamm Dis. 2023; 11(11):e1063.
PMID: 38018599
PMC: 10629237.
DOI: 10.1002/iid3.1063.
Machado P, Schafer M, Mahil S, Liew J, Gossec L, Dand N
Ann Rheum Dis. 2023; 82(5):698-709.
PMID: 36787993
PMC: 10176347.
DOI: 10.1136/ard-2022-223499.
Liu M, Wang H, Liu L, Cui S, Huo X, Xiao Z
Front Immunol. 2022; 13:1046352.
PMID: 36389759
PMC: 9648142.
DOI: 10.3389/fimmu.2022.1046352.
Campanati A, Diotallevi F, Martina E, Radi G, Offidani A
J Clin Med. 2022; 11(9).
PMID: 35566548
PMC: 9101352.
DOI: 10.3390/jcm11092422.
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.
Niedzwiedzka-Rystwej P, Majchrzak A, Kurkowska S, Malkowska P, Sierawska O, Hrynkiewicz R
Int J Mol Sci. 2022; 23(9).
PMID: 35562935
PMC: 9105989.
DOI: 10.3390/ijms23094545.
Erythrodermic flare-up of psoriasis with COVID-19 infection: A report of two cases and a comprehensive review of literature focusing on the mutual effect of psoriasis and COVID-19 on each other along with the special challenges of the pandemic.
Behrangi E, Sadeghzadeh-Bazargan A, Salimi N, Shaka Z, Kazemi M, Goodarzi A
Clin Case Rep. 2022; 10(4):e05722.
PMID: 35474976
PMC: 9019895.
DOI: 10.1002/ccr3.5722.
Biologics for Psoriasis During the COVID-19 Pandemic.
Zeng H, Wang S, Chen L, Shen Z
Front Med (Lausanne). 2021; 8:759568.
PMID: 34938746
PMC: 8685238.
DOI: 10.3389/fmed.2021.759568.
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.
Jahaj E, Vassiliou A, Keskinidou C, Gallos P, Vrettou C, Tsipilis S
J Pers Med. 2021; 11(9).
PMID: 34575667
PMC: 8466794.
DOI: 10.3390/jpm11090891.
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.
Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E
Br J Dermatol. 2021; 186(1):59-68.
PMID: 34310699
PMC: 8444811.
DOI: 10.1111/bjd.20659.
The signal pathways and treatment of cytokine storm in COVID-19.
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y
Signal Transduct Target Ther. 2021; 6(1):255.
PMID: 34234112
PMC: 8261820.
DOI: 10.1038/s41392-021-00679-0.
The Role of Th17 Response in COVID-19.
Martonik D, Parfieniuk-Kowerda A, Rogalska M, Flisiak R
Cells. 2021; 10(6).
PMID: 34205262
PMC: 8235311.
DOI: 10.3390/cells10061550.
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?.
Patsatsi A, Kyriakou A
Clin Dermatol. 2021; 39(1):52-55.
PMID: 33972053
PMC: 7834280.
DOI: 10.1016/j.clindermatol.2020.12.012.
Biologics for Psoriasis during the COVID-19 Pandemic.
Kamiya K, Komine M, Ohtsuki M
J Clin Med. 2021; 10(7).
PMID: 33808455
PMC: 8036429.
DOI: 10.3390/jcm10071390.
COVID-19 in Immunocompromised Hosts: What We Know So Far.
Fung M, Babik J
Clin Infect Dis. 2021; 72(2):340-350.
PMID: 33501974
PMC: 7337668.
DOI: 10.1093/cid/ciaa863.
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments.
Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G
Vaccines (Basel). 2020; 8(4).
PMID: 33276686
PMC: 7761600.
DOI: 10.3390/vaccines8040728.
Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations.
Garduno-Soto M, Choreno-Parra J, Cazarin-Barrientos J
Arch Dermatol Res. 2020; 313(8):611-622.
PMID: 33159236
PMC: 7646711.
DOI: 10.1007/s00403-020-02156-0.
Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea.
Cho S, Kim Y, Jo S
Br J Dermatol. 2020; 184(2):296-303.
PMID: 32875557
PMC: 9213995.
DOI: 10.1111/bjd.19507.
Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.
Giuliani F, Gualdi G, Amerio P
Dermatol Ther. 2020; 33(6):e14204.
PMID: 32829511
PMC: 7461363.
DOI: 10.1111/dth.14204.
SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor.
Foti R, Amato G, Visalli E
Med Hypotheses. 2020; 144:110040.
PMID: 32744241
PMC: 7328605.
DOI: 10.1016/j.mehy.2020.110040.
